QT Imaging Holdings (QTI) Investor presentation summary

Mission and market need

• Aims to transform breast health with a scalable, safe, high-resolution 3D imaging platform for dense breast diagnostics and precision oncology.

• Addresses limitations of mammography, MRI, and ultrasound, offering a pain-free, operator-independent solution validated and FDA cleared.

• Targets a $6B breast imaging market, with a focus on dense breast supplemental screening and biomarker-driven precision diagnostics.

Technology and clinical validation

• FDA-cleared, patent-protected breast imaging modality uses quantitative transmission and reflection ultrasound for high-resolution, 3D imaging.

• No radiation, compression, or contrast; exam time is 10–12 minutes per breast, suitable for dense breasts and implants.

• Clinical studies at Mayo Clinic and Sunnybrook Cancer Center show strong agreement with MRI for detection and treatment monitoring.

• Ongoing and planned studies at leading institutions; received $18M NIH funding and UAE regulatory approval.

Value proposition and patient experience

• Provides a single-step, patient-friendly process that reduces unnecessary biopsies and patient anxiety.

• Operator independence, low recall rates, and potential for higher revenue and lower labor costs compared to traditional methods.

• Biomarkers and AI integration enable early malignancy detection, therapy monitoring, and personalized medicine.